ES2524251T3 - Proteínas de tipo interferón humano recombinantes - Google Patents

Proteínas de tipo interferón humano recombinantes Download PDF

Info

Publication number
ES2524251T3
ES2524251T3 ES07720038.4T ES07720038T ES2524251T3 ES 2524251 T3 ES2524251 T3 ES 2524251T3 ES 07720038 T ES07720038 T ES 07720038T ES 2524251 T3 ES2524251 T3 ES 2524251T3
Authority
ES
Spain
Prior art keywords
human interferon
recombinant human
type proteins
interferon type
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07720038.4T
Other languages
English (en)
Inventor
Haitao Wang
Chunsheng Mao
Jizhi Li
Ling Wang
Yong Du
Longbin Liu
Jing Xu
Rui Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novagen Holding Corp
Original Assignee
Novagen Holding Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novagen Holding Corp filed Critical Novagen Holding Corp
Application granted granted Critical
Publication of ES2524251T3 publication Critical patent/ES2524251T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)

Abstract

Un polinucleótido aislado que codifica para una proteína que tiene actividades biológicas de tipo interferón humano, seleccionándose dicho polinucleótido del grupo que consiste en polinucleótidos que comprenden cada uno una secuencia nucleotídica al menos un 95 % idéntica a la SEC ID Nº: 1, y en el que la proteína tiene una actividad anti-proliferativa al menos 10 veces mayor que el interferón humano alfa 2b (HuIFN-a2b).

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30

Claims (1)

  1. imagen1
ES07720038.4T 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes Active ES2524251T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US764786 2007-06-18
US11/764,786 US7625555B2 (en) 2007-06-18 2007-06-18 Recombinant human interferon-like proteins
PCT/CA2007/001123 WO2008154719A1 (en) 2007-06-18 2007-06-22 Recombinant human interferon-like proteins

Publications (1)

Publication Number Publication Date
ES2524251T3 true ES2524251T3 (es) 2014-12-04

Family

ID=40132903

Family Applications (2)

Application Number Title Priority Date Filing Date
ES07720038.4T Active ES2524251T3 (es) 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes
ES12159128.3T Active ES2586398T3 (es) 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES12159128.3T Active ES2586398T3 (es) 2007-06-18 2007-06-22 Proteínas de tipo interferón humano recombinantes

Country Status (20)

Country Link
US (8) US7625555B2 (es)
EP (3) EP2465935B1 (es)
JP (3) JP5439189B2 (es)
KR (2) KR20130027043A (es)
CN (3) CN103483443A (es)
AU (1) AU2007355415B2 (es)
BR (1) BRPI0716948B1 (es)
CA (1) CA2692358C (es)
DK (2) DK2465935T3 (es)
ES (2) ES2524251T3 (es)
IL (1) IL196673A (es)
MX (1) MX2009001366A (es)
MY (1) MY167485A (es)
NZ (1) NZ574306A (es)
PL (2) PL2465935T3 (es)
PT (2) PT2465935T (es)
RU (1) RU2469091C2 (es)
TW (1) TWI375716B (es)
WO (1) WO2008154719A1 (es)
ZA (1) ZA200901680B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
MX2012010148A (es) 2010-03-04 2013-01-22 Pfenex Inc Metodo para producir proteinas de interferon recombinantes solubles sin desnaturalizacion.
AU2014322046B2 (en) * 2013-09-20 2021-02-04 Daiichi Sankyo Company, Limited Complex containing oligonucleotide having immunopotentiating activity and use thereof
LT6164B (lt) 2013-10-15 2015-06-25 Uab Biotechnologinės Farmacijos Centras "Biotechpharma" Sulieti interferono-alfa 5 baltymai su kitu citokinu ir jų gamybos būdas
US10519209B2 (en) * 2014-07-14 2019-12-31 Gennova Biopharmaceuticals Limited Process for purification of rHu-GCSF
WO2018041973A1 (en) * 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018101151A1 (ja) * 2016-12-02 2018-06-07 興人ライフサイエンス株式会社 リボース含有酵母調味料
US10780931B2 (en) * 2018-05-21 2020-09-22 Ronald Siwicki Kickstand assembly
CN109627343A (zh) * 2018-12-27 2019-04-16 北京美福源生物医药科技有限公司 长效细胞因子基因衍生物融合蛋白
CN113289006A (zh) * 2020-02-24 2021-08-24 杰华生物技术(青岛)有限公司 一种重组细胞因子基因衍生蛋白或其片段的用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US369922A (en) 1887-09-13 Jacket for steam-cylinders
US2004200A (en) * 1931-10-02 1935-06-11 Union Switch & Signal Co Lamp socket adapter
US3699222A (en) 1958-03-11 1972-10-17 Nat Res Dev Production of viral interfering substances
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
GB2148299B (en) 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
GB8412564D0 (en) 1984-05-17 1984-06-20 Searle & Co Structure and properties
ATE78262T1 (de) 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8803365D0 (en) 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5681811A (en) 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
HUT75533A (en) 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
CA2311681A1 (en) 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
US6685933B1 (en) 1998-07-28 2004-02-03 The United States Of America As Represented By The Department Of Health And Human Services Interferon α hybrids
US6514729B1 (en) 1999-05-12 2003-02-04 Xencor, Inc. Recombinant interferon-beta muteins
US7431921B2 (en) 1999-08-27 2008-10-07 Maxygen Aps Interferon beta-like molecules
KR20020034181A (ko) 1999-08-27 2002-05-08 맥시겐 에이피에스 새로운 인터페론 베타-유사 분자
US6531122B1 (en) 1999-08-27 2003-03-11 Maxygen Aps Interferon-β variants and conjugates
US20040002474A1 (en) 1999-10-07 2004-01-01 Maxygen Inc. IFN-alpha homologues
AU8001300A (en) 1999-10-07 2001-05-10 Maxygen, Inc. Ifn-alpha homologues
JP2003513681A (ja) 1999-11-12 2003-04-15 マキシゲン・ホールディングス・リミテッド インターフェロンガンマ・コンジュゲート
IT1317835B1 (it) * 2000-02-15 2003-07-15 San Raffaele Centro Fond Citochine modificate per uso nella terapia del cancro.
AU2001244711A1 (en) 2000-03-31 2001-10-08 Mochida Pharmaceutical Co., Ltd. Tlr/cd14 binding inhibitor
WO2002036628A2 (en) 2000-11-02 2002-05-10 Maxygen Aps New multimeric interferon beta polypeptides
EP1355939A2 (en) 2000-11-03 2003-10-29 Pestka Biomedical Laboratories, Inc. Interferons, uses and compositions related thereto
EP1366075B1 (en) 2001-02-27 2009-05-27 Maxygen Aps New interferon beta-like molecules
US6958388B2 (en) 2001-04-06 2005-10-25 Maxygen, Aps Interferon gamma polypeptide variants
US7038015B2 (en) 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
PL366705A1 (en) 2001-04-06 2005-02-07 Maxygen Holdings Ltd. Interferon gamma polypeptide variants
FR2825102B1 (fr) 2001-05-23 2003-08-29 Genodyssee Nouveaux polynucleotides et polypeptides de l'interferon alpha 14
WO2003002152A2 (en) 2001-06-29 2003-01-09 Maxygen Aps Stabilized formulations of interferons with sulfoalkyl ether cyclodextrins
CN1431018A (zh) 2002-01-10 2003-07-23 北京东康龙病毒生物技术工程研究中心 抗HSV感染和镇痛的人甲硫氨酸脑啡肽干扰素α－m融合蛋白制剂
WO2003075944A2 (en) 2002-03-12 2003-09-18 Maxygen Aps Interferon beta-like molecules for treatment of stroke
WO2004005341A2 (en) 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7314613B2 (en) 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
NZ540043A (en) 2002-11-18 2007-11-30 Maxygen Inc Isolated or recombinant Interferon-alpha polypeptides and conjugates
JP2006526022A (ja) * 2003-05-23 2006-11-16 ペスカ バイオメディカル ラボラトリーズ， インク． 重症急性呼吸器症候群及び他のウィルス感染の治療のためのインターフェロンの使用
WO2005113592A2 (en) 2004-05-19 2005-12-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
CA2607651A1 (en) * 2005-05-18 2007-04-19 Maxygen, Inc. Evolved interferon-alpha polypeptides
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins

Also Published As

Publication number Publication date
US20190077843A1 (en) 2019-03-14
US7868151B2 (en) 2011-01-11
KR101384307B1 (ko) 2014-05-21
US7625555B2 (en) 2009-12-01
JP2016117753A (ja) 2016-06-30
US20080312148A1 (en) 2008-12-18
EP2078082A4 (en) 2009-12-16
EP2465935A2 (en) 2012-06-20
US20130189226A1 (en) 2013-07-25
ZA200901680B (en) 2010-03-31
JP5439189B2 (ja) 2014-03-12
US9234022B2 (en) 2016-01-12
IL196673A0 (en) 2011-08-01
CN101432428B (zh) 2013-06-19
CN103483443A (zh) 2014-01-01
JP6099095B2 (ja) 2017-03-22
JP2010515466A (ja) 2010-05-13
PT2078082E (pt) 2014-11-27
CN102250918A (zh) 2011-11-23
EP2078082A1 (en) 2009-07-15
US20100129904A1 (en) 2010-05-27
TWI375716B (en) 2012-11-01
US10538565B2 (en) 2020-01-21
US20200369741A1 (en) 2020-11-26
WO2008154719A1 (en) 2008-12-24
RU2469091C2 (ru) 2012-12-10
US9982028B2 (en) 2018-05-29
MX2009001366A (es) 2009-04-17
TW200900504A (en) 2009-01-01
US20100099612A1 (en) 2010-04-22
US20100303759A1 (en) 2010-12-02
EP2078082B1 (en) 2014-08-20
HK1171048A1 (en) 2013-03-15
ES2586398T3 (es) 2016-10-14
PT2465935T (pt) 2016-08-05
CN101432428A (zh) 2009-05-13
NZ574306A (en) 2012-07-27
EP2465935A3 (en) 2012-08-15
AU2007355415B2 (en) 2012-07-26
EP2465935B1 (en) 2016-05-18
HK1129128A1 (zh) 2009-11-20
JP2014036657A (ja) 2014-02-27
PL2078082T3 (pl) 2015-02-27
RU2009104749A (ru) 2010-11-20
US20170015723A1 (en) 2017-01-19
IL196673A (en) 2015-08-31
CA2692358A1 (en) 2008-12-24
DK2078082T3 (en) 2014-12-01
PL2465935T3 (pl) 2017-08-31
MY167485A (en) 2018-08-30
EP3133161A1 (en) 2017-02-22
BRPI0716948B1 (pt) 2022-04-05
US7867482B2 (en) 2011-01-11
US8425895B2 (en) 2013-04-23
KR20130027043A (ko) 2013-03-14
CA2692358C (en) 2012-11-20
KR20100033468A (ko) 2010-03-30
AU2007355415A1 (en) 2008-12-24
DK2465935T3 (en) 2016-08-22
BRPI0716948A2 (pt) 2013-02-19

Similar Documents

Publication Publication Date Title
ES2545895T3 (es) Proteína de fusión anticancerígena
MX348464B (es) Agente inductor de inmunidad.
ES2569365T3 (es) Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular
ES2531391T3 (es) Delta-5 desaturasas y procedimiento para la preparación de ácidos grasos poliinsaturados en organismos transgénicos no humanos
DE602005020121D1 (de) Aus wt1 stammende krebsantigenpeptide
ES2531290T3 (es) Transferasas y oxidorreductasas, ácidos nucleicos que las codifican y métodos para prepararlas y usarlas
AR109680A1 (es) Proteínas recombinantes y sus usos
AR049177A1 (es) Polipeptidos y conjugados de interferon-alfa
AR050095A1 (es) Secuencias de subinidades pequenas de sintasa acetohidroxiacida de monocotiledoneas y metodos de uso.
ATE529442T1 (de) Verbesserte humane interferon-moleküle und ihre verwendungen
AR092076A1 (es) Proteinas homodimericas
AR110748A1 (es) Proteínas toxinas pesticidas activas contra insectos lepidópteros
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
ATE553124T1 (de) Oxyntomodulinanaloga und ihre wirkungen auf das fressverhalten
CL2012001631A1 (es) Proteínas aisladas correspondientes a variantes de la proteina insecticidas cry1ca, polinuleotidos que las codifican, celulas huesped y plantas transformadas con dichos acidos nucleicos, y metodo de control de pestes de insectos.
AR071534A1 (es) Peptidos aislados que tienen actividad inhibitoria de la fosfolipasa
ES2662325T3 (es) Inductor de respuesta inmune
ES2489715T3 (es) Procedimiento para la produccíón de colágeno humano de tipo II
ES2545614T3 (es) Proteínas truncadas con nudo de cistina
MY167485A (en) Recombinant human interferon-like proteins
ES2609586T3 (es) Secuencias de nucleótidos y aminoácidos que codifican una proteína exportada 1 derivada de Plasmodium vivax y usos de las mismas
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
ES2536238T3 (es) Péptidos antimicrobianos
DK200601181A (da) Fiskevaccine
ES2633468T3 (es) Agente inductor de inmunidad y método para la detección del cáncer